RxDoctor Payments Data

Thanh Huynh, MD

Family Medicine · Burlingame, CANPI 1962463026

Payments from drug & device makers

$4,588in general payments, 2019–2025

Across 211 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$794
  • GSK$699
  • AstraZeneca$638
  • Scilex Pharmaceuticals Inc.$636
  • Amgen$386
  • Lilly USA, LLC$351
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,56499%
  • Education$241%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,588 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$200,977
Medicare patients
268
Services billed
1,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin229$321,296
TrulicityDulaglutide139$217,643
OzempicSemaglutide77$122,075
EliquisApixaban85$102,011
JanuviaSitagliptin Phosphate48$57,536
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$50,686
ArexvyRsvpref3 Antigen/As01e/Pf127$38,921
XareltoRivaroxaban31$35,603
DescovyEmtricitabine/Tenofov Alafenam11$27,463
IsentressRaltegravir Potassium11$24,901
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate60$21,860
EntrestoSacubitril/Valsartan21$19,936
BreynaBudesonide/Formoterol Fumarate56$19,114
Breo ElliptaFluticasone/Vilanterol36$18,042
Atorvastatin Calcium766$17,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$138$321,296229 claims
Lilly USA, LLCTrulicity$351$217,643139 claims
Novo NordiskOzempic$794$122,07577 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Anoro Ellipta, Shingrix$699$119,453240 claims
PfizerEliquis, Paxlovid$336$114,794110 claims
MerckJanuvia, Isentress$52$82,43659 claims
Johnson & JohnsonXarelto$91$35,60331 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$638$28,15453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →